WO2014073992A1 - Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and the use of thereof. - Google Patents

Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and the use of thereof. Download PDF

Info

Publication number
WO2014073992A1
WO2014073992A1 PCT/PL2013/000114 PL2013000114W WO2014073992A1 WO 2014073992 A1 WO2014073992 A1 WO 2014073992A1 PL 2013000114 W PL2013000114 W PL 2013000114W WO 2014073992 A1 WO2014073992 A1 WO 2014073992A1
Authority
WO
WIPO (PCT)
Prior art keywords
vanadium
complexes
atom
group
diseases
Prior art date
Application number
PCT/PL2013/000114
Other languages
English (en)
French (fr)
Inventor
Ryszard GRYBOŚ
Janusz SZKLARZEWICZ
Dariusz MATOGA
Grzegorz KAZEK
Marek STĘPNIEWSKI
Mirosław KROŚNIAK
Gabriel NOWAK
Patrycja PACIOREK
Piotr ZABIEROWSKI
Original Assignee
Uniwersytet Jagiellonski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagiellonski filed Critical Uniwersytet Jagiellonski
Publication of WO2014073992A1 publication Critical patent/WO2014073992A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/005—Compounds of elements of Group 5 of the Periodic System without metal-carbon linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
PCT/PL2013/000114 2012-11-07 2013-09-10 Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and the use of thereof. WO2014073992A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL401493A PL231079B1 (pl) 2012-11-07 2012-11-07 Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
PLP.401493 2012-11-07

Publications (1)

Publication Number Publication Date
WO2014073992A1 true WO2014073992A1 (en) 2014-05-15

Family

ID=49486638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2013/000114 WO2014073992A1 (en) 2012-11-07 2013-09-10 Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and the use of thereof.

Country Status (2)

Country Link
PL (1) PL231079B1 (pl)
WO (1) WO2014073992A1 (pl)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432354A (zh) * 2016-09-30 2017-02-22 山西大学 一种席夫碱钯配合物及其制备方法和应用
CN106749393A (zh) * 2017-01-09 2017-05-31 山西大学 皮考啉腙酸衍生物双氧钒（v）配合物及其制备方法
CN108623625A (zh) * 2018-07-11 2018-10-09 山东理工大学 具有类胰岛素活性的有机钒配合物及其制备方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB328157A (en) 1929-06-17 1930-04-24 Ernest Edward Palmer Improvements in and relating to manifolding books
US4882171A (en) 1986-10-16 1989-11-21 Posner Barry I Vanadium-peroxide compositions as insulin mimickers
US5155031A (en) 1990-06-07 1992-10-13 Posner Barry I Use of pervanadate as an inhibitor of phosphotyrosine phosphatase
US5266565A (en) 1991-07-03 1993-11-30 Adir Et Compagnie Vanadium complexes
US5338759A (en) 1991-10-07 1994-08-16 Yeda Research And Development Co. Ltd. Vanadyl complexes of hydroxamate chelators and pharmaceutical compositions comprising them
US5583242A (en) 1994-01-31 1996-12-10 Bristol-Myers Squibb Company Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation
US6414029B1 (en) 1997-09-11 2002-07-02 Yeda Research And Development Co. Ltd. Vanadium complexes of monohydroxamates and pharmaceutical compositions comprising them
US6432941B1 (en) 1998-01-20 2002-08-13 Parker Hughes Institute Vanadium compounds for treating cancer
US6579540B1 (en) 1997-07-29 2003-06-17 Gho'st Holding B.V. Use of physiologically acceptable vanadium compounds, salts and complexes
US7692012B2 (en) 2003-12-04 2010-04-06 Imperial College Innovations Limited Vanadium compounds as inhibitors of phosphatases
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
US8242092B2 (en) 2008-02-05 2012-08-14 Brent Townshend Protein tyrosine phosphatase inhibitors

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB328157A (en) 1929-06-17 1930-04-24 Ernest Edward Palmer Improvements in and relating to manifolding books
US4882171A (en) 1986-10-16 1989-11-21 Posner Barry I Vanadium-peroxide compositions as insulin mimickers
US5155031A (en) 1990-06-07 1992-10-13 Posner Barry I Use of pervanadate as an inhibitor of phosphotyrosine phosphatase
US5266565A (en) 1991-07-03 1993-11-30 Adir Et Compagnie Vanadium complexes
US5278154A (en) 1991-07-03 1994-01-11 Adir Et Compagnie New vanadium complexes
US5338759A (en) 1991-10-07 1994-08-16 Yeda Research And Development Co. Ltd. Vanadyl complexes of hydroxamate chelators and pharmaceutical compositions comprising them
US5583242A (en) 1994-01-31 1996-12-10 Bristol-Myers Squibb Company Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation
US5877210A (en) 1994-01-31 1999-03-02 Bristol-Myers Squibb Company Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation
US6579540B1 (en) 1997-07-29 2003-06-17 Gho'st Holding B.V. Use of physiologically acceptable vanadium compounds, salts and complexes
US6414029B1 (en) 1997-09-11 2002-07-02 Yeda Research And Development Co. Ltd. Vanadium complexes of monohydroxamates and pharmaceutical compositions comprising them
US6432941B1 (en) 1998-01-20 2002-08-13 Parker Hughes Institute Vanadium compounds for treating cancer
US7692012B2 (en) 2003-12-04 2010-04-06 Imperial College Innovations Limited Vanadium compounds as inhibitors of phosphatases
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
US8242092B2 (en) 2008-02-05 2012-08-14 Brent Townshend Protein tyrosine phosphatase inhibitors

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
ADACHI Y.; SAKURAI H., CHEM. PHARM. BULL., vol. 52, 2004, pages 428
BLUNT M.D.; WARD S.G., CURR. OPIN. PHARMACOL., vol. 12, 2012, pages 444
BRAITHWAITE S.P.; STOCK J.B.; LOMBROSO P.J.; NAIRN A.C., PROG. MOL. BIOL. TRANSL. SCI., vol. 106, no. 212, pages 343
BRAITHWAITE S.P.; VORONKOV M.; STOCK J.B.; MOURADIAN M.M., NEUROCHEM. INT., vol. 61, 2012, pages 899
CRANS D.C.; YANG L.; ALFANO J. A.; CHI L.H.; JIN W.; MAHROOF-TAHIR M.; ROBBINS K.; TOLOUE M.M.; CHAN L.K.; PLANTE A.J., COORD. CHEM. REV., vol. 237, 2003, pages 13
DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002718279, retrieved from STN Database accession no. 1974:127647 *
GAO L.; NIU Y.; LIU W.; XIE M.; LIU X.; CHEN Z.; LI L., CLIN. CHIM. ACTA, vol. 388, 2008, pages 89
HAMRIN K.; HENRIKSSON J., LIFE SCI., vol. 76, 2005, pages 2329
HAN H.; LU L.; WANG Q.; ZHU M.; YUAN C.; XING S.; FU X., DALTON TRANS., vol. 41, 2012, pages 11116
ISLAM M.N.; KUMBHAR A.A.; KUMBHAR A.S.; ZELLER M.; BUTCHER R.J.; DUSANE M.B.; JOSHI B.N., INORG CHEM., vol. 49, 2010, pages 8237
JESSICA M. FAUTCH ET AL.: "Solution speciation, kinetics and observing reaction intermediates in the alkylation of oxidovanadium compounds", INORG. CHEM., vol. 49, 2010, pages 4791 - 4801, XP002718277 *
KATOH A.; MATSUMURA Y.; YOSHIKAWA Y.; YASUI H.; SAKURAI H., J. INORG. BIOCHEM., vol. 103, 2009, pages 567
MAURYA M. R.; AGARWAL S.; BADER C.; EBEL M.; REHDER D., DALTON TRANS., 2005, pages 537
MAURYA, M. R., COORD. CHEM. REV., vol. 237, 2003, pages 163
MEHDI M.Z.; SRIVASTAVA A.K., ARCH. BIOCHEM. BIOPHYS., vol. 440, 2005, pages 158
MONAFARED H.H.; BIKAS R.; MAYER P., INORG. CHIM. ACTA, vol. 363, 2010, pages 2574
MONFARED H H ET AL: "Homogeneous green catalysts for olefin oxidation by mono oxovanadium(V) complexes of hydrazone Schiff base ligands", INORGANICA CHIMICA ACTA, ELSEVIER BV, NL, vol. 363, no. 11, 10 August 2010 (2010-08-10), pages 2574 - 2583, XP027460594, ISSN: 0020-1693, [retrieved on 20100513], DOI: 10.1016/J.ICA.2010.04.046 *
NILSSON J.; DEGERMAN E.; HAUKKA M.; LISENSKY G.C.; GARRIBBA E.; YOSHIKAWA Y.; SAKURAI H.; ENYEDY E.A.; KISS T.; ESBAK H., J. CHEM. SOC., DALTON TRANS., 2009, pages 7902
OXIDOVANADIUM COMPLEXES FOR THE CONSUMPTION OF ALKYLATING TOXINS, EUR. J. INORG. CHEM., vol. 2009, 2009, pages 33 - 37, XP002718278 *
PAGANO M.A.; TIBALDI E.; GRINGERI E.; BRUNATI A.M., IUBMB LIFE, vol. 64, 2012, pages 27
PLASS, W., COORD. CHEM. REV., vol. 255, 2011, pages 2378
SAKURAI H.; KATOH A.; YOSHIKAWA Y., BULL. CHEM. SOC. JPN., vol. 79, 2006, pages 1645
SAKURAI H.; WATANABE H.; TAMURA H.; YASUI H.; MATSUSHITA R.; TAKADA J., INORG. CHIM. ACTA, vol. 283, 1998, pages 175
SCHMID A.C.; BYRNE R.D.; VILAR R.; WOSCHOLSKI R., FEBS LETT., vol. 566, 2004, pages 35
SCIOR T.; GUEVARA-GARCIAA.; BERNARDP., DOQ.; DOMEYER D.; LAUFER S., MINI-REV.MED. CHEM., vol. 5, 2005, pages 995
SEENA E. B.; MATHEW N.; KURIAKOSE M.; KURUP M. R. P., POLYHEDRON, vol. 27, 2008, pages 1455
SEENA ET AL: "Synthesis, spectral and EPR studies of oxovanadium(IV) complexes incorporating tridentate ONO donor hydrazone ligands: Structural study of one oxovanadium(V) complex", POLYHEDRON, PERGAMON PRESS, OXFORD, GB, vol. 27, no. 5, 6 March 2008 (2008-03-06), pages 1455 - 1462, XP022534520, ISSN: 0277-5387, DOI: 10.1016/J.POLY.2008.01.020 *
SREEJA P. B.; KURUP M. R. P., SPECTROCHIM. ACTA A, vol. 61, 2005, pages 331
SUN H.; WANG Y., PHYSIOLOGY (BETHESDA, vol. 27, 2012, pages 43
THOMPSON K. H.; MCNEILL J. H.; ORVIG C., CHEM. REV., vol. 99, 1999, pages 2561
THOMPSON K.H.; ORVIG C., COORD. CHEM. REV., vol. 219-221, 2001, pages 1033
THOMPSON K.H.; ORVIG C., J. INORG. BIOCHEM., vol. 100, 2006, pages 1925
TRACEY A.S., J. INORG. BIOCHEM., vol. 80, 2000, pages 11
VARDATSIKOS G.; MEHDI M.Z.; SRIVASTAVA A.K., INT. J. MOL. MED., vol. 24, 2009, pages 303
WELTE, S.; BARINGHAUS KH; SCHMIDER W.; MULLER, G.; S. PETRY; TENNAGELS N., ANAL. BIOCHEM, vol. 338, 2005, pages 32
XU Y.; FISHER G.J., J. CELL. COMMUN. SIGNAL., vol. 6, 2012, pages 125
ZHI-XI HANG ET AL.: "Two new oxovanadium(V) complexes with hydrazone ligands as insulin mimetics: synthesis and crystal structures", SYNTHESIS AND REACTIVITY IN INORGANIC AND NANO-METAL CHEMISTRY, vol. 42, October 2012 (2012-10-01), pages 1351 - 1355, XP008166470 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432354A (zh) * 2016-09-30 2017-02-22 山西大学 一种席夫碱钯配合物及其制备方法和应用
CN106749393A (zh) * 2017-01-09 2017-05-31 山西大学 皮考啉腙酸衍生物双氧钒（v）配合物及其制备方法
CN108623625A (zh) * 2018-07-11 2018-10-09 山东理工大学 具有类胰岛素活性的有机钒配合物及其制备方法

Also Published As

Publication number Publication date
PL231079B1 (pl) 2019-01-31
PL401493A1 (pl) 2014-05-12

Similar Documents

Publication Publication Date Title
Del Carpio et al. Vanadium: History, chemistry, interactions with α-amino acids and potential therapeutic applications
You et al. Schiff base transition metal complexes as novel inhibitors of xanthine oxidase
McLauchlan et al. Inhibition of acid, alkaline, and tyrosine (PTP1B) phosphatases by novel vanadium complexes
EP0440626B1 (en) Synthetic gtf chromium material and process therefor
US4954492A (en) Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
Soldevila-Barreda et al. Half-sandwich rhodium (III) transfer hydrogenation catalysts: Reduction of NAD+ and pyruvate, and antiproliferative activity
Zümreoglu-Karan The coordination chemistry of Vitamin C: An overview
Kazancı et al. Synthesis, characterization and bioactivities of dative donor ligand N-heterocyclic carbene (NHC) precursors and their Ag (I) NHC coordination compounds
Reytman et al. Highly effective and hydrolytically stable vanadium (V) amino phenolato antitumor agents
NL8301324A (nl) Farmaceutisch preparaat dat een nh2-(ch2)3-c(po3h2)oh-verbinding bevat.
Bacchi et al. From ligand to complexes. Part 2. Remarks on human immunodeficiency virus type 1 integrase inhibition by β-diketo acid metal complexes
Khan et al. Gold (I), silver (I) and copper (I) complexes of 2, 4, 6-trimethylphenyl-3-benzoylthiourea; synthesis and biological applications
Liu et al. Fluorescent iridium (III) coumarin-salicylaldehyde Schiff base compounds as lysosome-targeted antitumor agents
WO2014073992A1 (en) Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and the use of thereof.
Kamatchi et al. New organometallic ruthenium (II) complexes containing chelidonic acid (4-oxo-4 H-pyran-2, 6-dicarboxylic acid): synthesis, structure and in vitro biological activity
CN104169291B (zh) 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法
Zhou et al. Synthesis, crystal structures and insulin-like activity of three new oxidovanadium (V) complexes with aroylhydrazone ligand
Hashmi et al. Medicinal applications of vanadium complexes with Schiff bases
EP1224192B1 (en) Half-sandwich ruthenium (ii) compounds comprising nitrogen containing ligands for treatment of cancer
Chkirate et al. Solvent induced supramolecular polymorphism in Cu (II) coordination complex built from 1, 2, 4-triazolo [1, 5-a] pyrimidine: Crystal structures and anti-oxidant activity
Lobana et al. Di-2-pyridylketone-N1-substituted thiosemicarbazone derivatives of copper (II): Biosafe antimicrobial potential and high anticancer activity against immortalized L6 rat skeletal muscle cells
US20090247492A1 (en) Manganese based organometallic complexes, pharmaceutical compositions and dietetic products
CN109810128B (zh) 一种以2-吡啶甲醛缩氨基硫脲为配体的铟配合物及其合成方法和应用
Chakraborty et al. A combined experimental and theoretical rationalization of an unusual zinc (II)-mediated conversion of 18-membered Schiff-base macrocycles to 18-membered imine–amine macrocycles with imidazolidine side rings: An investigation of their bio-relevant catalytic activities
Loughrey et al. Novel organometallic cationic ruthenium (II) pentamethylcyclopentadienyl benzenesulfonamide complexes targeted to inhibit carbonic anhydrase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13783113

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13783113

Country of ref document: EP

Kind code of ref document: A1